Refractec ViewPoint Approval Should Reflect Lack Of Long-Term Data – Panel

Refractec should modify the proposed labeling for its ViewPoint conductive keratoplasty system to reflect a dearth of long-term efficacy data, FDA's Ophthalmic Devices Panel recommended Nov. 30 in voting 9-1 for the device's approval